Диссеминированный рак яичников: современный подход к лекарственной терапии (обзор литературы)

Диссеминированный рак яичников: современный подход к лекарственной терапии (обзор литературы)

Автор: Молчанов Сергей Валериевич, Коломиец Лариса Александровна

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Обзоры

Статья в выпуске: 6 (72), 2015 года.

Бесплатный доступ

В обзоре представлены данные литературы по вопросам лекарственной терапии рака яичников, в том числе неоадъювантной, интраперитонеальной, гипертермической интраперитонеальной химиотерапии. Обсуждаются перспективы использования таргетной терапии при данной патологии.

Рак яичников, неоадъювантная химиотерапия, интраперитонеальная химиотерапия, гипертермическая интраперитонеальная химиотерапия, таргетная терапия

Короткий адрес: https://sciup.org/14056603

IDR: 14056603

Список литературы Диссеминированный рак яичников: современный подход к лекарственной терапии (обзор литературы)

  • Гервас П.А., Литвяков Н.В., Попова Н.О., Добродеев А.Ю., Тарасова А.С., Юмов Е.Л., Иванова Ф.Г., Черемисина О.В., Афанасьев С.Г., Гольдберг В.Е., Чердынцева Н.В. Проблемы и перспективы совершенствования молекулярно-генетической диагностики для назначения таргетных препаратов в онкологии//Сибирский онкологический журнал. 2014. № 2. С. 46-55.
  • Злокачественные новообразования в России в 2009 году (заболеваемость и смертность)/Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2011. 260 с.
  • Молчанов С.В., Коломиец Л.А. Диссеминированный рак яичников: возможности хирургического лечения (обзор литературы)//Сибирский онкологический журнал. 2014. № 5. С. 54-59.
  • Молчанов С.В., Коломиец Л.А., Фролова И.Г., Вяткина Н.В., Бакланова Н.С. Перитонеальный канцероматоз при раке яичников: эхосемиотика, классификация//Вестник РОНЦ им. Н.Н. Блохина РАМН. 2014. Т. 25, № 1-2. С. 14-20.
  • Тюляндин С.А., Покатаев И.А., Тюляндина А.С., Кузнецов В.В., Жорданиа К.И., Стенина М.Б. Лечение распространенного рака яичников: Итоги работы отделения клинической фармакологии и химиотерапии РОНЦ им. Н.Н. Блохина РАМН за 1999-2010 гг.//Вестник Российской академии медицинских наук. 2011. № 12. С. 4-9.
  • Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., Copeland L.J., Walker J.L., Burger R.A. Intraperitoneal cisplatin and paclitaxel in ovarian cancer//N. Engl. J. Med. 2006. Vol. 354 (1). P. 34-43.
  • Bristow R.E., Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a metaanalysis//Gynecol. Oncol. 2006. Vol. 103 (3). P. 1070-1076.
  • Burger R.A., Brady M.F., Rhee J., Sovak M.A., Kong G., Nguyen H.P., Bookman M.A. Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer//Gynecol. Oncol. 2013. Vol. 131 (1). P. 21-26. doi: 10.1016/j. ygyno.2013.07.100.
  • Burger R.A., Sill M.W., Monk B.J., Greer B.E., Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study//J. Clin. Oncol. 2007. Vol. 25 (33). P. 5165-5171.
  • Byrne A.T., Ross L., Holash J., Nakanishi M., Hu L., Hofmann J.I., Yancopoulos G.D., Jaffe R.B. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model//Clin. Cancer Res. 2003. Vol. 9 (15). P. 5721-5728.
  • Cannistra S.A., Matulonis U.A., Penson R.T., Hambleton J., Dupont J., Mackey H., Douglas J., Burger R.A., Armstrong D., Wenham R., McGuire W. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer//J. Clin. Oncol. 2007. Vol. 25 (33). P. 5180-5186.
  • de Bree E., Tsiftsis D.D. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: From laboratory bench to bedside//Recent Results Cancer Res. 2007. Vol. 169. P. 53-73.
  • Diaz-Montes T.P., Bristow R.E. Secondary cytoreduction for patients with recurrent ovarian cancer//Curr. Oncol. Rep. 2005. Vol. 7 (6). P. 451-458.
  • Friedlander M., Hancock K.C., Rischin D., Messing M.J., Stringer C.A., Matthys G.M., Ma B., Hodge J.P., Lager J.J. A phase II open-label study evaluating pazopanib in patients with recurrent ovarian cancer//Gynecol. Oncol. 2010. Vol. 119 (1). P. 32-37. doi: 10.1016/j. ygyno.2010.05.033.
  • Fujiwara K., Armstrong D., Morgan M., Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer//Int. J. Gynecol. Cancer. 2007. Vol. 17 (1). P. 1-20.
  • Gelmon K.A., Tischkowitz M., Mackay H., Swenerton K., Robidoux A., Tonkin K., Hirte H., Huntsman D., Clemons M., Gilks B., Yerushalmi R., Macpherson E., Carmichael J., Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study//Lancet Oncology. 2011. Vol. 12 (9). P. 852-861. doi: 10.1016/S1470-2045(11)70214-5.
  • Giannopoulos T., Butler-Manuel S., Taylor A., Ngeh N., Thomas H. Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma//Eur. J. Gynecol. Oncol. 2006. Vol. 27 (1). P. 25-28.
  • Gori J., Castano R., Toziano M., Häbich D., Staringer J., DeQuirós D.G., Felci N. Intraperitoneal hyperthermic chemotherapy in ovarian cancer//Int. J. Gynecol. Cancer. 2005. Vol. 15 (2). P. 233-239.
  • Hainsworth J.D., Numnum T.M., Rao G.G. A randomized phase II study of paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer//J. Clin. Oncol. 2010. Vol. 28. Suppl. 15s. Abs. TPS257.
  • Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings//Mol. Oncol. 2011. Vol. 5 (4). P. 387-393 DOI: 10.1016/j.molonc.2011.07.001
  • Helm C.W., Richard S.D., Pan J., Bartlett D., Goodman M.D., Hoefer R., Lentz S.S., Levine E.A., Loggie B.W., Metzinger D.S., Miller B., Parker L., Spellman J.E., Sugarbaker P.H., Edwards R.P., Rai S.N. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry//Int. J. Gynecol. Cancer. 2010. Vol. 20 (1). P. 61-69 DOI: 10.1111/IGC.0b013e3181c50cde
  • Hou J.Y., Kelly M.G., Yu H., McAlpine J.N., Azodi M., Rutherford T.J., Schwartz P.E. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease//Gynecol. Oncol. 2007. Vol. 105 (1). P. 211-217.
  • Kang S., Nam B.H. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies//Ann. Surg. Oncol. 2009. Vol. 16 (8). P. 2315-2320 DOI: 10.1245/s10434-009-0558-6
  • Kumar L., Hariprasad R., Kumar S. et al. Neoadjuvant chemotherapy in advanced epithelial ovarian oancer (EOC): a Phase III randomized study//J. Clin. Oncol. (Meeting Abstracts). 2006. Vol. 24. Suppl. 18. Abs. 15000.
  • Ledermann J.A., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., Scott C., Meier W., Shapira-Frommer R., Safra T., Matei D., Macpherson E., Watkins C., Carmichael J., Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer//N. Engl. J. Med. 2012. Vol. 366 (15). P. 1382-1392. doi: 10.1056/NEJ-Moa1105535.
  • Ledermann J.A., Rustin G.J., Hackshaw A. et al. A randomized phase II placebo controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer//J. Clin. Oncol. 2009. Vol. 27. Suppl. 15s. Abs. 5501.
  • Matulonis U.A., Berlin S., Ivy P., Tyburski K., Krasner C., Zarwan C., Berkenblit A., Campos S., Horowitz N., Cannistra S.A., Lee H., Lee J., Roche M., Hill M., Whalen C., Sullivan L., Tran C., Humphreys B.D., Penson R.T. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer//J. Clin. Oncol. 2009. Vol. 27 (33). P. 5601-5606 DOI: 10.1200/JCO.2009.23.2777
  • Menczer J., Usviatzov I., Ben-Shem E., Golan A., Levy T. Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival?//J. Gynecol. Oncol. 2011. Vol. 22 (3). P. 183-187 DOI: 10.3802/jgo.2011.22.3.183
  • Micha J.P., Goldstein B.H., Rettenmaier M.A., Genesen M., Graham C., Bader K., Lopez K.L., Nickle M., Brown J.V. 3rd. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advancedstage epithelial ovarian, peritoneal, and fallopian tube cancer//Int. J. Gynecol. Cancer. 2007. Vol. 17 (4). P. 771-776.
  • Miyagi Y., Fujiwara K., Kigawa J., Itamochi H., Nagao S., Aotani E., Terakawa N., Kohno I. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy: a comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs intravenous infusion of carboplatin -a Sankai Gynecology Study Group (SGSG) study//Gynecol. Oncol. 2005. Vol. 99 (3). P. 591-596.
  • Onda T., Yoshikawa H. Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions//Exp. Rev. Anticancer Ther. 2011. Vol. 11 (7). P. 1053-1067. doi: 10.1586/era.11.24.
  • Parson E.N., Lentz S., Russell G., Shen P., Levine E.A., Stewart J.H. 4th. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms//Am. J. Surg. 2011. Vol. 202 (4). P. 481-486. doi: 10.1016/j. amjsurg.2011.02.004.
  • Perren T., Swart A.M., Pfisterer J. et al. ICON7: A phase III randomized gynecologic cancer intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevecizumab versus chemotherapy alone in women with new diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer//Ann. Oncol. 2010. Vol. 21. Suppl. 8. P. LBA4.
  • Rose P.G., Drake R., Braly P.S. et al. Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube//J. Clin. Oncol. ASCO Annual Meeting. 2009. Vol. 27. Abs. 5546.
  • Roviello F., Pinto E., Corso G., Pedrazzani C., Caruso S., Filippeschi M., Petrioli R., Marsili S., Mazzei M.A., Marrelli D. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer//J. Surg. Oncol. 2010. Vol. 102 (6). P. 663-670 DOI: 10.1002/jso.21682
  • Rufián S., Muñoz-Casares F.C., Briceño J., Díaz C.J., Rubio M.J., Ortega R., Ciria R., Morillo M., Aranda E., Muntané J., Pera C. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer//J. Surg. Oncol. 2006. Vol. 94 (4). P. 316-324.
  • Ryu K.S., Kim J.H., Ko H.S., Kim J.W., Ahn W.S., Park Y.G., Kim S.J., Lee J.M. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer//Gynecol. Oncol. 2004. Vol. 94 (2). P. 325-332.
  • Santillan A., Karam A. K., Li A.J., Giuntoli R. 2nd, Gardner G.J., Cass I. Karlan B.Y., Bristow R.E. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer//Gynecol. Oncol. 2007. Vol. 104 (3). P. 686-690.
  • Shen G.H., Ghazizadeh M., Kawanami O., Shimizu H., Jin E., Araki T., Sugisaki Y. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma//Br. J. Cancer. 2000. Vol. 83 (2). P. 196-203.
  • Steed H., Oza A.M., Murphy J., Laframboise S., Lockwood G., Petrillo D.E., Sturgeon J., Rosen B. Aretrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer//Int. J. Gynecol. Cancer. 2006. Vol. 16. Suppl. 1. P. 47-53.
  • Sticca R.P., Dach B.W. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents//Surg. Oncol. Clin. N. Am. 2003. Vol. 12 (3). P. 689-701.
  • Takemoto M., Kuroda M., Urano M., Nishimura Y., Kawasaki S., Kato H., Okumura Y., Akaki S., Kanazawa S., Asaumi J., Joja I., Hiraki Y. The effect of various chemotherapeutic agents given at mild hyperthermia on different types of tumors//Int. J. Hyperthermia. 2003. Vol. 19 (2). P. 193-203.
  • Trimble E.L., Christian M.C. National Cancer Institute -United States strategy regarding intraperitoneal chemotherapy for ovarian cancer//Int. J. Gynecol. Cancer. 2008. Vol. 18. Suppl. 1. P. 26-28 DOI: 10.1111/j.1525-1438.2007.01100.x
  • Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R., Parkin D., Paul J., Hay A., Kaye S.B. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma//J. Natl. Cancer Inst. 2004. Vol. 96 (22). P. 1682-1691.
  • Vergote I., Tropé C.G., Amant F., Kristensen G.B., Ehlen T., Johnson N., Verheijen R.H., van der Burg M.E., Lacave A.J., Panici P.B., Kenter G.G., Casado A., Mendiola C., Coens C., Verleye L., Stuart G.C., Pecorelli S., Reed N.S. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer//N. Engl. J. Med. 2010. Vol. 363 (10). P. 943-953 DOI: 10.1056/NEJMoa0908806
  • Walker J.L., Armstrong D.K., Huang H.Q., Fowler J., Webster K., Burger R.A., Clarke-Pearson D. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study//Gynecol. Oncol. 2006. Vol. 100 (1). P. 27-32.
  • Weinberg L.E., Rodriguez G., Hurteau J.A. The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer//J. Surg. Oncol. 2010. Vol. 101 (4). P. 334-343 DOI: 10.1002/jso.21482
Еще
Статья обзорная
SciUp 2024 © 2024 ©